|Bid||2.1100 x 1100|
|Ask||0.0000 x 900|
|Day's Range||2.6000 - 3.0000|
|52 Week Range||2.0500 - 8.2440|
|Beta (5Y Monthly)||2.33|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 29, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||11.75|
Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today provided a corporate update and reported financial results for the fourth quarter and year ended December 31, 2019.
NEW YORK, NY / ACCESSWIRE / March 30, 2020 / Alpine Immune Sciences, Inc. (NASDAQ:ALPN) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on March 30, 2020 ...
Alpine Immune Sciences, Inc. (NASDAQ:ALPN) , a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today announced the United States Food and Drug Administration (FDA) has made two orphan drug designations for ALPN-101, Alpine’s first-in-class selective dual T cell costimulation inhibitor, for the prevention and for the treatment of acute GVHD.
Alpine Immune Sciences, Inc. (NASDAQ:ALPN) announced today the cancellation of the Company’s presentation and webcast at the Cowen 40th Annual Healthcare Conference scheduled for Tuesday, March 3, 2020 at 11:20 am. Eastern Time. The Company is taking precautionary measures in response to the evolving coronavirus (COVID-19) situation in the Seattle area.
Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading immunotherapy company focused on developing treatments for autoimmune/inflammatory diseases and cancer, today announced the company will present at two upcoming investor healthcare conferences in March.
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. On...
Hedge funds and large money managers usually invest with a focus on the long-term horizon and, therefore, short-lived dips or bumps on the charts, usually don't make them change their opinion towards a company. This time it may be different. During the fourth quarter of 2018 we observed increased volatility and a 20% drop in […]
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 12) ACADIA Pharmaceuticals Inc (NASDAQ: ACAD ) Allergan ...
Every investor in Alpine Immune Sciences, Inc. (NASDAQ:ALPN) should be aware of the most powerful shareholder groups...
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Alpine Immune Sciences (ALPN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The simplest way to benefit from a rising market is to buy an index fund. When you buy individual stocks, you can make...